Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Escitalopram versus citalopram: the surprising role of the R-enantiomer.

Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C.

Psychopharmacology (Berl). 2004 Jul;174(2):163-76. Review.

PMID:
15160261
2.

[Escitalopram and citalopram: the unexpected role of the R-enantiomer].

Jacquot C, David DJ, Gardier AM, Sánchez C.

Encephale. 2007 Mar-Apr;33(2):179-87. Review. French.

PMID:
17675913
3.

Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram.

Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R, Spindelegger C, Asenbaum S, Holik A, Dudczak R.

Int Clin Psychopharmacol. 2009 May;24(3):119-25. doi: 10.1097/YIC.0b013e32832a8ec8. Review.

PMID:
19367152
4.

Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.

Leonard B, Taylor D.

J Psychopharmacol. 2010 Aug;24(8):1143-52. doi: 10.1177/0269881109349835. Epub 2010 Feb 10. Review.

5.
6.

Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.

Sánchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O.

Psychopharmacology (Berl). 2003 Jun;167(4):353-62. Epub 2003 Apr 26.

PMID:
12719960
7.

[Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].

Mnie-Filali O, El Mansari M, Scarna H, Zimmer L, Sánchez C, Haddjeri N.

Encephale. 2007 Dec;33(6):965-72. doi: 10.1016/j.encep.2007.11.001. Epub 2007 Dec 11. Review. French.

PMID:
18789789
8.

Escitalopram.

Aronson S, Delgado P.

Drugs Today (Barc). 2004 Feb;40(2):121-31. Review.

PMID:
15045034
9.

[Mechanisms of action of antidepressants: new data from Escitalopram].

Fabre V, Hamon M.

Encephale. 2003 May-Jun;29(3 Pt 1):259-65. French.

PMID:
12876551
10.

Escitalopram: a unique mechanism of action.

Bræstrup C, Sanchez C.

Int J Psychiatry Clin Pract. 2004;8 Suppl 1:11-3. doi: 10.1080/13651500410005496.

PMID:
24930683
11.

Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.

Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sánchez C, Haddjeri N.

Int J Neuropsychopharmacol. 2007 Feb;10(1):31-40. Epub 2006 Feb 1.

PMID:
16448580
12.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
13.

[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].

Azorin JM, Llorca PM, Despiegel N, Verpillat P.

Encephale. 2004 Mar-Apr;30(2):158-66. French.

PMID:
15107719
14.

Escitalopram: better treatment for depression is through the looking glass.

Malin P, Wengel SP, Burke WJ.

Expert Rev Neurother. 2004 Sep;4(5):769-79. Review.

PMID:
15853504
15.

Managing depressive and anxiety disorders with escitalopram.

Thase ME.

Expert Opin Pharmacother. 2006 Mar;7(4):429-40. Review.

PMID:
16503815
16.

[Escitalopram--second generation of serotonin transporter inhibitors?].

Rybakowski J, Borkowska AB.

Psychiatr Pol. 2004 Mar-Apr;38(2):227-39. Review. Polish.

PMID:
15307289
17.

Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.

Zhong H, Haddjeri N, Sánchez C.

Psychopharmacology (Berl). 2012 Jan;219(1):1-13. doi: 10.1007/s00213-011-2463-5. Epub 2011 Sep 8. Review.

PMID:
21901317
18.
19.

[Escitalopram for treatment of major depressive disorder in adults].

Llorca PM, Brousse G, Schwan R.

Encephale. 2005 Jul-Aug;31(4 Pt 1):490-501. Review. French.

PMID:
16389716
20.

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.

Montgomery SA, Loft H, Sánchez C, Reines EH, Papp M.

Pharmacol Toxicol. 2001 May;88(5):282-6.

PMID:
11393591

Supplemental Content

Support Center